TABLE 3.
Patient Survival Times in Relation to BRAF Mutation Status and Administration of BRAFi
| Variable | Entire Cohort | Group A | Group B | Group C |
|---|---|---|---|---|
| No. of patients | 198 | 23 | 67 | 108 |
| Survival after diagnosis of primary melanoma | ||||
| MST in mo (95% CI) | 61 (46-76) | 47 (0-116) | 99 (43.7-154.3) | 47 (35.3-58.7) |
| 1-yr survival % | 89.9 | 87.0 | 97.0 | 86.1 |
| 3-yr survival % | 59.6 | 60.9 | 67.2 | 54.6 |
| 5-yr survival % | 39.9 | 34.8 | 50.7 | 34.3 |
| Survival after diagnosis of BM | ||||
| MST in mo (95% CI) | 10.9 (8.2-13.6) | 36 (0-72.6) | 16 (9.5-22.5) | 9 (7.7-10.3) |
| 0.5-yr survival % | 75.3 | 69.6 | 85.1 | 70.4 |
| 1-yr survival % | 40.9 | 39.1 | 56.7 | 31.5 |
| 2-yr survival % | 19.2 | 34.8 | 25.4 | 11.1 |
| Survival after SRS | ||||
| MST in mo (95% CI) | 8.4 (5.9-10.9) | 36 (0-76.1) | 13 (9.4-16.7) | 7 (5.6-8.4) |
| 0.5-yr survival % | 64.1 | 65.2 | 70.1 | 60.2 |
| 1-yr survival % | 37.4 | 34.8 | 52.2 | 28.7 |
| 2-yr survival % | 15.7 | 30.4 | 20.9 | 8.3 |
CI = confidence interval; MST = median survival time.